Single answer
Is Aligos Therapeutics Inc (ALGS) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Aligos Therapeutics Inc is $3.00, which is $6.32 (67.83%) below the current price today's price.
Low target: $3.00 | High target: $3.00
Company snapshot
A quick overview of the business and its public profile.
Aligos Therapeutics Inc a clinicalstage biopharmaceutical company focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases Its lead drug candidate is ALG010133 a santigen transportinhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B CHB and ALG000184 a capsid assembly modulator which is in Phase I clinical trials to treat CHB The company also develops ALG020572 an antisense oligonucleotide to prevent HBsAg translation and secretion and ALG055009 a small molecule THRss agonist that is in the Phase 1a1b for the treatment of nonalcoholic steatohepatitisNASH In addition it develops siRNA drug candidate ALG125755 as well as ALG125097 and ALG125819 demonstrated potent inhibition of HBsAg release from HBVinfected cells It has entered into license and collaboration agreements with Luxna Biotech Co Ltd to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome Emory University to provide hepatitis B virus capsid assembly modulator technology research licensing and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors and Merck to discover research optimize and develop oligonucleotides directed against a NASH The company was incorporated in 2018 and is headquartered in South San Francisco California
Website: https://www.aligos.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.06. Cash flow to debt ratio: -13.05. Net profit margin: -4,538.69%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
No, the average daily trading liquidity for Aligos Therapeutics Inc is $768,338. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
10-year return check
We cannot find data for Aligos Therapeutics Inc 10 years ago, but if you had invested on 2020-10-16 when the price was $14.85, you would have made a loss of $5.73 per share or 38.59%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.